Technical Analysis for REVB - Revelation Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.95 | 5.69% | 0.11 |
Earnings due: May 20
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 5.69% | |
NR7 | Range Contraction | 5.69% | |
Narrow Range Bar | Range Contraction | 5.69% | |
Inside Day | Range Contraction | 5.69% | |
Below Lower BB | Weakness | 5.69% | |
Lower Bollinger Band Touch | Weakness | 5.69% | |
Oversold Stochastic | Weakness | 5.69% | |
Stochastic Reached Oversold | Weakness | 5.98% | |
Below Lower BB | Weakness | 5.98% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 17 hours ago |
Up 1% | about 17 hours ago |
Rose Above Lower Bollinger Band | about 20 hours ago |
Rose Above Lower Bollinger Band | 1 day ago |
Up 2% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/20/2024
Revelation Biosciences, Inc. Description
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Disease Immunology Infection Vaccination Respiratory Diseases Allergology Nasal Administration Rhinitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 39.0 |
52 Week Low | 1.7801 |
Average Volume | 84,468 |
200-Day Moving Average | 12.87 |
50-Day Moving Average | 2.39 |
20-Day Moving Average | 2.15 |
10-Day Moving Average | 2.16 |
Average True Range | 0.22 |
RSI (14) | 38.65 |
ADX | 11.39 |
+DI | 21.31 |
-DI | 25.13 |
Chandelier Exit (Long, 3 ATRs) | 1.84 |
Chandelier Exit (Short, 3 ATRs) | 2.44 |
Upper Bollinger Bands | 2.45 |
Lower Bollinger Band | 1.84 |
Percent B (%b) | 0.18 |
BandWidth | 28.46 |
MACD Line | -0.15 |
MACD Signal Line | -0.14 |
MACD Histogram | -0.0021 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.19 | ||||
Resistance 3 (R3) | 2.18 | 2.09 | 2.15 | ||
Resistance 2 (R2) | 2.09 | 2.03 | 2.10 | 2.14 | |
Resistance 1 (R1) | 2.02 | 1.99 | 2.06 | 2.03 | 2.12 |
Pivot Point | 1.93 | 1.93 | 1.95 | 1.94 | 1.93 |
Support 1 (S1) | 1.86 | 1.87 | 1.90 | 1.87 | 1.78 |
Support 2 (S2) | 1.77 | 1.83 | 1.78 | 1.76 | |
Support 3 (S3) | 1.70 | 1.77 | 1.75 | ||
Support 4 (S4) | 1.71 |